{"disease":{"id":"metastatic-mismatch-repair-proficient-colorectal-carcinoma","name":"metastatic mismatch repair proficient colorectal carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06730100","title":"CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04119830","title":"Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}